Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Revenues Slide

NEW YORK, Feb. 5 – Compgen today reported revenue decreases for the fourth quarter and for the year today.

The Tel Aviv, Israel-based company saw revenues fall to $11.1 million in 2002 from $11.4 million for 2001, and $2.7 million in the fourth quarter compared to $3.1 million for the year-ago quarter.

The company said it began 2003 with $67.3 million in cash and cash-related accounts with an anticipated burn rate for 2003 of $15.3 million.

Compugen said that it expects research and development expense will continue to account for over 50 percent of its total operating expenses. The company had R&D expenses of $3.6 million in the fourth quarter, compared to $3.5 million for the same quarter in 2001; and $13.6 million for the year; compared to $14.3 million in 2001.

Net loss for the year was $12.2 million, including a non-cash charge of $861,000 for amortization of deferred compensation, or $.12 a share. Net loss for the quarter ending Dec. 31, 2002, was $3.2 million, or $.12 a share, compared to $4.1 million, or $.16 a share, in the year-ago quarter.

 

 

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.